Cargando…

Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity

Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient....

Descripción completa

Detalles Bibliográficos
Autores principales: Atrsaei, Arash, Corrà, Marta Francisca, Dadashi, Farzin, Vila-Chã, Nuno, Maia, Luis, Mariani, Benoit, Maetzler, Walter, Aminian, Kamiar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935857/
https://www.ncbi.nlm.nih.gov/pubmed/33674597
http://dx.doi.org/10.1038/s41531-021-00171-0
_version_ 1783661082613645312
author Atrsaei, Arash
Corrà, Marta Francisca
Dadashi, Farzin
Vila-Chã, Nuno
Maia, Luis
Mariani, Benoit
Maetzler, Walter
Aminian, Kamiar
author_facet Atrsaei, Arash
Corrà, Marta Francisca
Dadashi, Farzin
Vila-Chã, Nuno
Maia, Luis
Mariani, Benoit
Maetzler, Walter
Aminian, Kamiar
author_sort Atrsaei, Arash
collection PubMed
description Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient. The goal of this study was to investigate objectively under what conditions during daily activities, patients perform as well as or better than in the clinic. To this end, we recruited 27 Parkinson’s disease (PD) patients and measured their gait speed by inertial measurement units through several walking tests in the clinic as well as their daily activities at home. By fitting a bimodal Gaussian model to their gait speed distribution, we found that on average, patients had similar modes in the clinic and during daily activities. Furthermore, we observed that the number of medication doses taken throughout the day had a moderate correlation with the difference between clinic and home. Performing a cycle-by-cycle analysis on gait speed during the home assessment, overall only about 3% of the strides had equal or greater gait speeds than the patients’ capacity in the clinic. These strides were during long walking bouts (>1 min) and happened before noon, around 26 min after medication intake, reaching their maximum occurrence probability 3 h after Levodopa intake. These results open the possibility of better control of medication intake in PD by considering both functional capacity and continuous monitoring of gait speed during real-life conditions.
format Online
Article
Text
id pubmed-7935857
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79358572021-03-19 Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity Atrsaei, Arash Corrà, Marta Francisca Dadashi, Farzin Vila-Chã, Nuno Maia, Luis Mariani, Benoit Maetzler, Walter Aminian, Kamiar NPJ Parkinsons Dis Article Gait speed often referred as the sixth vital sign is the most powerful biomarker of mobility. While a clinical setting allows the estimation of gait speed under controlled conditions that present functional capacity, gait speed in real-life conditions provides the actual performance of the patient. The goal of this study was to investigate objectively under what conditions during daily activities, patients perform as well as or better than in the clinic. To this end, we recruited 27 Parkinson’s disease (PD) patients and measured their gait speed by inertial measurement units through several walking tests in the clinic as well as their daily activities at home. By fitting a bimodal Gaussian model to their gait speed distribution, we found that on average, patients had similar modes in the clinic and during daily activities. Furthermore, we observed that the number of medication doses taken throughout the day had a moderate correlation with the difference between clinic and home. Performing a cycle-by-cycle analysis on gait speed during the home assessment, overall only about 3% of the strides had equal or greater gait speeds than the patients’ capacity in the clinic. These strides were during long walking bouts (>1 min) and happened before noon, around 26 min after medication intake, reaching their maximum occurrence probability 3 h after Levodopa intake. These results open the possibility of better control of medication intake in PD by considering both functional capacity and continuous monitoring of gait speed during real-life conditions. Nature Publishing Group UK 2021-03-05 /pmc/articles/PMC7935857/ /pubmed/33674597 http://dx.doi.org/10.1038/s41531-021-00171-0 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Atrsaei, Arash
Corrà, Marta Francisca
Dadashi, Farzin
Vila-Chã, Nuno
Maia, Luis
Mariani, Benoit
Maetzler, Walter
Aminian, Kamiar
Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_full Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_fullStr Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_full_unstemmed Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_short Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity
title_sort gait speed in clinical and daily living assessments in parkinson’s disease patients: performance versus capacity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935857/
https://www.ncbi.nlm.nih.gov/pubmed/33674597
http://dx.doi.org/10.1038/s41531-021-00171-0
work_keys_str_mv AT atrsaeiarash gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT corramartafrancisca gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT dadashifarzin gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT vilachanuno gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT maialuis gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT marianibenoit gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT maetzlerwalter gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity
AT aminiankamiar gaitspeedinclinicalanddailylivingassessmentsinparkinsonsdiseasepatientsperformanceversuscapacity